Novavax Inc SEC filings NVAX
Novavax Inc has 1,003 filings in SEC EDGAR's recent list, going back to Feb 14, 2013. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Jun 18, 2026 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 20, 2025 |
| DEFA14A | Additional proxy material | Jun 5, 2024 | — |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 13, 2024 |
| DEFA14A | Additional proxy material | Jul 7, 2023 | — |
| DEFA14A | Additional proxy material | Jun 29, 2023 | — |
| DEFA14A | Additional proxy material | Jun 20, 2023 | — |
| DEFA14A | Additional proxy material | Jun 15, 2023 | — |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | — |
| PRE 14A | Preliminary proxy statement | Apr 18, 2023 | — |
| DEFA14A | Additional proxy material | May 3, 2022 | — |
| DEF 14A | Proxy statement | May 2, 2022 | Jun 16, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2022 | Jun 16, 2022 |
| DEFA14A | Additional proxy material | May 27, 2021 | — |
| DEFA14A | Additional proxy material | May 24, 2021 | — |
| DEFA14A | Additional proxy material | May 3, 2021 | — |
| DEF 14A | Proxy statement | May 3, 2021 | Jun 17, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 21, 2021 | Jun 17, 2021 |
| DEFA14A | Additional proxy material | Jun 18, 2020 | — |
| DEFA14A | Additional proxy material | May 13, 2020 | — |
| DEF 14A | Proxy statement | May 13, 2020 | Jun 25, 2020 |
| DEFA14A | Additional proxy material | May 16, 2019 | — |
| DEF 14A | Proxy statement | May 16, 2019 | Jun 28, 2019 |
| DEF 14A | Proxy statement | Apr 1, 2019 | May 8, 2019 |
| PRE 14A | Preliminary proxy statement | Mar 21, 2019 | Mar 21, 2019 |
| DEFA14A | Additional proxy material | Apr 30, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 14, 2018 |
| DEFA14A | Additional proxy material | Apr 28, 2017 | — |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 15, 2017 |
| DEFA14A | Additional proxy material | Apr 20, 2016 | — |
| DEF 14A | Proxy statement | Apr 20, 2016 | Jun 9, 2016 |
| DEFA14A | Additional proxy material | Apr 30, 2015 | — |
| DEF 14A | Proxy statement | Apr 30, 2015 | Jun 18, 2015 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2015 | Apr 20, 2015 |
| DEF 14A | Proxy statement | Apr 30, 2014 | Jun 12, 2014 |
| DEF 14A | Proxy statement | Apr 30, 2013 | Jun 13, 2013 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2013 | Jun 13, 2013 |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- NVAX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Gaithersburg, MD
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1000694
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.